UPLOAD Filing
VERTEX PHARMACEUTICALS INC / MA
Date: March 18, 2026 · CIK: 0000875320 · Accession: 0000000000-26-002758
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 000-19319
Letter
March 18, 2026 Charles F. Wagner, Jr. Executive Vice President and Chief Operating & Financial Officer Vertex Pharmaceuticals, Inc. 50 Northern Avenue Boston, MA 02210 Re:Vertex Pharmaceuticals, Inc. Form 10-K for Fiscal Year Ended December 31, 2025 File No. 000-19319 Dear Charles F. Wagner Jr.: We have limited our review of your filing to the financial statements and related disclosures and have the following comment. Please respond to this letter within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe a comment applies to your facts and circumstances, please tell us why in your response. After reviewing your response to this letter, we may have additional comments. Form 10-K for Fiscal Year Ended December 31, 2025 Financial Statements B. Collaboration, License and Other Arrangements Out-license Agreements, page F-20 1.We note your disclosure stating that you entered into collaboration agreements with Zai Lab Limited and Ono Pharmaceuticals Co. Ltd. In future filings, if material, please expand your disclosure to describe the material terms of these agreements including, but not limited to, the termination provisions and any royalty or milestone payment requirements. Disclose the royalty rate or a range not exceeding 10%. In addition, tell us how you considered whether to file the agreements as exhibits. In closing, we remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tracie Mariner at 202-551-3744 or Kevin Vaughn at 202-551-3494 with any questions.
March 18, 2026 Page 2 Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
March 18, 2026
Charles F. Wagner, Jr.
Executive Vice President and Chief Operating & Financial Officer
Vertex Pharmaceuticals, Inc.
50 Northern Avenue
Boston, MA 02210
Re:Vertex Pharmaceuticals, Inc.
Form 10-K for Fiscal Year Ended December 31, 2025
File No. 000-19319
Dear Charles F. Wagner Jr.:
We have limited our review of your filing to the financial statements and related
disclosures and have the following comment.
Please respond to this letter within ten business days by providing the requested
information or advise us as soon as possible when you will respond. If you do not believe a
comment applies to your facts and circumstances, please tell us why in your response.
After reviewing your response to this letter, we may have additional comments.
Form 10-K for Fiscal Year Ended December 31, 2025
Financial Statements
B. Collaboration, License and Other Arrangements
Out-license Agreements, page F-20
1.We note your disclosure stating that you entered into collaboration agreements with Zai
Lab Limited and Ono Pharmaceuticals Co. Ltd. In future filings, if material, please
expand your disclosure to describe the material terms of these agreements including, but
not limited to, the termination provisions and any royalty or milestone payment
requirements. Disclose the royalty rate or a range not exceeding 10%. In addition, tell us
how you considered whether to file the agreements as exhibits.
In closing, we remind you that the company and its management are responsible for the
accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or
absence of action by the staff.
Please contact Tracie Mariner at 202-551-3744 or Kevin Vaughn at 202-551-3494 with
any questions.
March 18, 2026
Page 2
Sincerely,
Division of Corporation Finance
Office of Life Sciences